Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: A longitudinal MRI study

Neurobiology of Aging

Volumn 31, Issue 8, 2010, Pages 1340-1354

  Tosun, Duygu ^a   Schuff, Norbert ^a,b   Truran Sacrey, Diana ^a   Shaw, Leslie M ^c   Trojanowski, John Q ^c   Aisen, Paul ^d   Peterson, Ronald ^e   Weiner, Michael W ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Mayo Clinic   (United States)

Author keywords

Alzheimer's disease; ApoE; Atrophy; Biomarkers; Brain tissue volume; Cerebrospinal fluid; Cortical thickness; Healthy aging; Mild cognitive impairment; MRI

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN REGION; CEREBROSPINAL FLUID ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; GENETIC PREDISPOSITION; HUMAN; HYPOTHESIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; ATROPHY; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; TAU PROTEINS;

EID: 77954030909     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.04.030     Document Type: Article

References (68)

1. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz B.E., Houck P.R., Bi W., Cohen A.D., Lopresti B.J., deKosky S.T., Halligan E.M., Klunk W.E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol 2008, 65:1509-1517.
2. Andersson C., Blennow K., Johansson S.E., Almkvist O., Engfeldt P., Lindau M., Eriksdotter-Jonhagen M. Differential CSF biomarker levels in APOE-e4-positive and -negative patients with memory impairment. Dement. Geriatr. Cognit. Disord 2007, 23:87-95.
3. Andreasen N., Minthon L., Vanmechelen E., Vanderstichele H., Davidsson P., Winblad B., Blennow K. Cerebrospinal fluid tau and A[beta] 42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett 1999, 273:5-8.
4. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1991, 1:103-116.
5. Basso M., Gelernter J., Yang J., MacAvoy M.G., Varma P., Bronen R.A., van Dyck C.H. Apolipoprotein E ε4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiol. Aging 2006, 27:1416-1424.
6. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B Stat. Methodol 1995, 57:289-300.
7. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
8. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
9. Brys M., Glodzik L., Mosconi L., Switalski R., De Santi S., Pirraglia E., Rich K., Kim B.C., Mehta P., Zinkowski R., Pratico D., Wallin A., Zetterberg H., Tsui W.H., Rusinek H., Blennow K., de Leon M.J. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J. Alzheimers Dis 2009, 16:351-362.
10. Chetelat G.A., Baron J.-C. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003, 18:525-541.
11. Chou Y.-Y., Lepor È.N., Avedissian C., Madsen S.K., Parikshak N., Hua X., Shaw L.M., Trojanowski J.Q., Weiner M.W., Toga A.W., Thompson P.M. Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage 2009, 46:394-410.
12. Clark C.M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., Morris J.C., McKeel D.W., Farlow M., Weitlauf S.L., Quinn J., Kaye J., Knopman D., Arai H., Doody R.S., deCarli C., Leight S., Lee V.M.-Y., Trojanowski J.Q. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch. Neurol 2003, 60:1696-1702.
13. deCarli C., Frisoni G.B., Clark C.M., Harvey D., Grundman M., Petersen R.C., Thal L.J., Jin S., Jack C.R., Scheltens P. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch. Neurol 2007, 64:108-115. Alzheimer's Disease Cooperative Study Group.
14. Desikan R.S., Fischl B., Cabral H.J., Kemper T.L., Guttmann C.R.G., Blacker D., Hyman B.T., Albert M.S., Killiany R.J. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology 2008, 71:819-825.
15. deToledo-Morrell L., Stoub T.R., Bulgakova M., Wilson R.S., Bennett D.A., Leurgans S., Wuu J., Turner D.A. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol. Aging 2004, 25:1197-1203.
16. Du A.T., Schuff N., Amend D., Laakso M.P., Hsu Y.Y., Jagust W.J., Yaffe K., Kramer J.H., Reed B., Norman D., Chui H.C., Weiner M.W. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2001, 71:441-447.
17. Du A.T., Schuff N., Kramer J.H., Ganzer S., Zhu X.P., Jagust W.J., Miller B.L., Reed B.R., Mungas D., Yaffe K., Chui H.C., Weiner M.W. Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology 2004, 62:422-427.
18. Du A.T., Schuff N., Laakso M.P., Zhu X.P., Jagust W.J., Yaffe K., Kramer J.H., Miller B.L., Reed B.R., Norman D., Chui H.C., Weiner M.W. Effects of subcortical ischemic vascular dementia and AD on entorhinal cortex and hippocampus. Neurology 2002, 58:1635-1641.
19. Du A.T., Schuff N., Zhu X.P., Jagust W.J., Miller B.L., Reed B.R., Kramer J.H., Mungas D., Yaffe K., Chui H.C., Weiner M.W. Atrophy rates of entorhinal cortex in AD and normal aging. Neurology 2003, 60:481-486.
20. Duarte A., Hayasaka S., Du A., Schuff N., Jahng G.-H., Kramer J., Miller B., Weiner M. Volumetric correlates of memory and executive function in normal elderly, mild cognitive impairment and Alzheimer's disease. Neurosci. Lett 2006, 406:60-65.
21. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., Holtzman D.M. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol 2009, 65:176-183.
22. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11050-11055.
23. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
24. Fischl B., van der Kouwe A., Destrieux C., Halgren E., Segonne F., Salat D.H., Busa E., Seidman L.J., Goldstein J., Kennedy D., Caviness V., Makris N., Rosen B., Dale A.M. Automatically parcellating the human cerebral cortex. Cereb. Cortex 2004, 14:11-22.
25. Fjell A.M., Walhovd K.B., Amlien I., Bjornerud A., Reinvang I., Gjerstad L., Cappelen T., Willoch F., Due-Tonnessen P., Grambaite R., Skinningsrud A., Stenset V., Fladby T. Morphometric changes in the episodic memory network and tau pathologic features correlate with memory performance in patients with mild cognitive impairment. AJNR Am. J. Neuroradiol 2008, 29:1183-1189.
26. Fjell, A.M., Walhovd, K.B., Fennema-Notestine, C., McEvoy, L.K., Hagler, D.J., Holland, D., Blennow, K., Brewer, J.B., Dale, A.M., Alzheimer's Disease Neuroimaging Initiative, 2010a. Brain atrophy in healthy aging is related to CSF levels of A{beta}1-42. Cereb. Cortex, in press doi:10.1093/cercor/bhp279.
27. Fjell A.M., Walhovd K.B., Fennema-Notestine C., McEvoy L.K., Hagler D.J., Holland D., Brewer J.B., Dale A.M. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J. Neurosci 2010, 30:2088-2101. Alzheimer's Disease Neuroimaging Initiative.
28. Fleisher A., Grundman M., Jack C.R., Petersen R.C., Taylor C., Kim H.T., Schiller D.H.B., Bagwell V., Sencakova D., Weiner M.F., deCarli C., deKosky S.T., van Dyck C.H., Thal L.J. Sex, apolipoprotein E {varepsilon}4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 2005, 62:953-957. Alzheimer's Disease Cooperative Study.
29. Glodzik-Sobanska L., Pirraglia E., Brys M., de Santi S., Mosconi L., Rich K.E., Switalski R., Louis L.S., Sadowski M.J., Martiniuk F., Mehta P., Pratico D., Zinkowski R.P., Blennow K., de Leon M.J. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol. Aging 2009, 30:672-681.
30. Hampel H., Burger K., Pruessner J.C., Zinkowski R., deBernardis J., Kerkman D., Leinsinger G., Evans A.C., Davies P., Moller H.-J., Teipel S.J. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch. Neurol 2005, 62:770-773.
31. 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry 2003, 9:705-710.
32. Henneman W.J.P., Vrenken H., Barnes J., Sluimer I.C., Verwey N.A., Blankenstein M.A., Klein M., Fox N.C., Scheltens P., Barkhof F., van der Flier W.M. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009, 73:935-940.
33. Herukka S.-K., Pennanen C., Soininen H., Pirttilä T. CSF Aβ42, Tau and Phosphorylated Tau Correlate with Medial Temporal Lobe Atrophy. J. Alzheimers Dis 2008, 14:51-57.
34. Hua X., Leow A.D., Lee S., Klunder A.D., Toga A.W., Lepore N., Chou Y.-Y., Brun C., Chiang M.-C., Barysheva M., Jack C.R., Bernstein M.A., Britson P.J., Ward C.P., Whitwell J.L., Borowski B., Fleisher A.S., Fox N.C., Boyes R.G., Barnes J., Harvey D., Kornak J., Schuff N., Boreta L., Alexander G.E., Weiner M.W., Thompson P.M. 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage 2008, 41:19-34. Alzheimer's Disease Neuroimaging Initiative.
35. Jack C.R., Bernstein M.A., Fox N.C., Thompson P., Alexander G., Harvey D., Borowski B., Britson P.J., Whitwell J.L., Ward C., Dale A.M., Felmlee J.P., Gunter J.L., Hill D.L.G., Killiany R., Schuff N., Fox-Bosetti S., Lin C., Studholme C., deCarli C.S., Krueger G., Ward H.A., Metzger G.J., Scott K.T., Mallozzi R., Blezek D., Levy J., Debbins J.P., Fleisher A.S., Albert M., Green R., Bartzokis G., Glover G., Mugler J., Weiner M.W. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J. Mag. Reson. Imaging 2008, 27:685-691.
36. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365. Alzheimer's Disease Neuroimaging Initiative.
37. Jack C.R., Shiung M.M., Weigand S.D., O'Brien P.C., Gunter J.L., Boeve B.F., Knopman D.S., Smith G.E., Ivnik R.J., Tangalos E.G., Petersen R.C. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005, 65:1227-1231.
38. Jack C.R., Weigand S.D., Shiung M.M., Przybelski S.A., O'Brien P.C., Gunter J.L., Knopman D.S., Boeve B.F., Smith G.E., Petersen R.C. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2008, 70:1740-1752.
39. Jack C.R., Shiung M.M., Gunter J.L., O'Brien P.C., Weigand S.D., Knopman D.S., Boeve B.F., Ivnik R.J., Smith G.E., Cha R.H., Tangalos E.G., Petersen R.C. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004, 62:591-600.
40. John H.G. Incorporating biomarkers into clinical drug trials in Alzheimer's disease. J. Alzheimers Dis 2001, 3:287-292.
41. Klunk W.E., Price J.C., Mathis C.A., Tsopelas N.D., Lopresti B.J., Ziolko S.K., Bi W., Hoge J.A., Cohen A.D., Ikonomovic M.D., Saxton J.A., Snitz B.E., Pollen D.A., Moonis M., Lippa C.F., Swearer J.M., Johnson K.A., Rentz D.M., Fischman A.J., Aizenstein H.J., deKosky S.T. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci 2007, 27:6174-6184.
42. Kramer J.H., Schuff N., Reed B.R., Mungas D., Du A.-T., Rosen H.J., Jagust W.J., Miller B.L., Weiner M.W., Chui H.C. Hippocampal volume and retention in Alzheimer's disease. J. Int. Neuropsychol. Soc 2004, 10:639-643.
43. Leow A.D., Yanovsky I., Parikshak N., Hua X., Lee S., Toga A.W., Jack C.R., Bernstein M.A., Britson P.J., Gunter J.L., Ward C.P., Borowski B., Shaw L.M., Trojanowski J.Q., Fleisher A.S., Harvey D., Kornak J., Schuff N., Alexander G.E., Weiner M.W., Thompson P.M. Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009, 45:645-655.
44. Mintun M.A., laRossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., deKosky S.T., Morris J.C. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
45. Morra J.H., Tu Z., Apostolova L.G., Green A.E., Avedissian C., Madsen S.K., Parikshak N., Hua X., Toga A.W., Jack C.R., Weiner M.W., Thompson P.M. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage 2008, 43:59-68.
46. Morra J.H., Tu Z., Apostolova L.G., Green A.E., Avedissian C., Madsen S.K., Parikshak N., Hua X., Toga A.W., Jack C.R., Schuff N., Weiner M.W., Thompson P.M. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum. Brain Mapp 2009, 30:2766-2788. Alzheimer's Disease Neuroimaging Initiative.
47. Morra J.H., Tu Z., Apostolova L.G., Green A.E., Avedissian C., Madsen S.K., Parikshak N., Toga A.W., Jack C.R., Schuff N., Weiner M.W., Thompson P.M. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage 2009, 45:S3-S15.
48. Olsson A., Vanderstichele H., Andreasen N., De Meyer G., Wallin A., Holmberg B., Rosengren L., Vanmechelen E., Blennow K. Simultaneous Measurement of {beta}amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP Technology. Clin. Chem 2005, 51:336-345.
49. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol 1999, 56:303-308.
50. Potkin S.G., Guffanti G., Lakatos A., Turner J.A., Kruggel F., Fallon J.H., Saykin A.J., Orro A., Lupoli S., Salvi E., Weiner M., Macciardi F. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One 2009, 4:e6501. Alzheimer's Disease Neuroimaging Initiative.
51. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol 1999, 45:358-368.
52. Scahill R.I., Schott J.M., Stevens J.M., Rossor M.N., Fox N.C. Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:4703-4707.
53. Schroeter M.L., Stein T., Maslowski N., Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. Neuroimage 2009, 47:1196-1206.
54. Schuff N., Woerner N., Boreta L., Kornfield T., Shaw L.M., Trojanowski J.Q., Thompson P.M., Jack C.R., Weiner M.W. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009, 132:1067-1077. Alzheimer's Disease Neuroimaging Initiative.
55. Shaw L.M., Korecka M., Clark C.M., Lee V.M.Y., Trojanowski J.Q. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov 2007, 6:295-303.
56. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M.-Y., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol 2009, 65:403-413. Initiative, A.s.D.N.
57. Skoog I., Davidsson P., Aevarsson O., Vanderstichele H., Vanmechelen E., Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement. Geriatr. Cogn. Disord 2003, 15:169-176.
58. Sluimer J.D., Vrenken H., Blankenstein M.A., Fox N.C., Scheltens P., Barkhof F., van der Flier W.M. Whole-brain atrophy rate in Alzheimer disease: Identifying fast progressors. Neurology 2008, 70:1836-1841.
59. Stefani A., Martorana A., Bernardini S., Panella M., Mercati F., Orlacchio A., Pierantozzi M. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J. Neurol. Sci 2006, 251:124-128.
60. Stomrud E., Hansson O., Blennow K., Minthon L., Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement. Geriatr. Cogn. Disord 2007, 24:118-124.
61. Stoub T.R., Bulgakova M., Leurgans S., Bennett D.A., Fleischman D., Turner D.A., deToledo-Morrell L. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 2005, 64:1520-1524.
62. Sunderland T., Mirza N., Putnam K.T., Linker G., Bhupali D., Durham R., Soares H., Kimmel L., Friedman D., Bergeson J., Csako G., Levy J.A., Bartko J.J., Cohen R.M. Cerebrospinal fluid-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE 4 allele. Biol. Psychiatry 2004, 56:670-676.
63. Thompson P.M., Hayashi K.M., de Zubicaray G., Janke A.L., Rose S.E., Semple J., Herman D., Hong M.S., Dittmer S.S., Doddrell D.M., Toga A.W. Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci 2003, 23:994-1005.
64. Thompson P.M., Hayashi K.M., de Zubicaray G.I., Janke A.L., Rose S.E., Semple J., Hong M.S., Herman D.H., Gravano D., Doddrell D.M., Toga A.W. Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 2004, 22:1754-1766.
65. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009, 73:287-293. Alzheimer's Disease Neuroimaging Initiative.
66. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009, 73:294-301. Alzheimer's Disease Neuroimaging Initiative.
67. Whitwell J.L., Przybelski S.A., Weigand S.D., Knopman D.S., Boeve B.F., Petersen R.C., Jack C.R. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007, 130:1777-1786.
68. Whitwell J.L., Shiung M.M., Przybelski S.A., Weigand S.D., Knopman D.S., Boeve B.F., Petersen R.C., Jack C.R. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008, 70:512-520.